Innovaccer Completes Rs 600 Crore ESOP Buyback

Innovaccer, a healthtech leader, has successfully carried out an ESOP buyback valued at Rs 600 crore, equivalent to around $75 million. This move offers liquidity to both present and former employees who possess vested stock options. As reported by Inc42, a number of employees, both current and former, holding restricted stock units, benefited from this buyback.

Details of the Buyback Following Series F Funding

This buyback follows Innovaccer’s impressive $275 million Series F funding round, which comprised both primary and secondary capital. This funding effort attracted several notable investors, including B Capital, Kaiser Permanente, and Generation Investment Management.

About Innovaccer

Founded in 2014, Innovaccer operates a sophisticated healthcare data and analytics platform that provides hospitals, health systems, and insurers with the tools to integrate clinical and operational data efficiently. The company has established a significant foothold in the US healthcare sector, forging strong partnerships with provider networks and payers.

Recent Financial Performance

For the fiscal year ending March 2025, Innovaccer reported operating revenue of Rs 387.71 crore along with a profit of Rs 36.1 crore. Under the leadership of Abhinav Shashank, the company has also expanded its capabilities by acquiring two firms, Cured and Pharmacy Quality Solutions, over the past year.

ESOP Buyback Trends in 2025

The timing of this buyback is notable, following the announcement of a $125 million ESOP liquidity programme by SaaS unicorn BrowserStack. In context, ESOP buyback activities in 2025 have been relatively quiet, totaling just over $75 million. This contrasts sharply with the cumulative ESOP buybacks, payouts, and liquidity of approximately $190 million in 2024, as well as $802 million in 2023, $440 million in 2021, and $200 million in 2022.